These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 16172033)

  • 1. Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients.
    Ratti L; Pozzi M; Bosch J
    Dig Liver Dis; 2005 Nov; 37(11):886-93. PubMed ID: 16172033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.
    Roberts S; Gordon A; McLean C; Pedersen J; Bowden S; Thomson K; Angus P
    Clin Gastroenterol Hepatol; 2007 Aug; 5(8):932-7. PubMed ID: 17544878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
    Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
    J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
    Everson GT; Balart L; Lee SS; Reindollar RW; Shiffman ML; Minuk GY; Pockros PJ; Govindarajan S; Lentz E; Heathcote EJ
    Aliment Pharmacol Ther; 2008 Apr; 27(7):542-51. PubMed ID: 18208570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.
    Carrión JA; Navasa M; García-Retortillo M; García-Pagan JC; Crespo G; Bruguera M; Bosch J; Forns X
    Gastroenterology; 2007 May; 132(5):1746-56. PubMed ID: 17484872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of etiological treatment on prognosis.
    Su CW; Yang YY; Lin HC
    Hepatol Int; 2018 Feb; 12(Suppl 1):56-67. PubMed ID: 28702738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
    Reiberger T; Payer BA; Ferlitsch A; Sieghart W; Breitenecker F; Aichelburg MC; Schmied B; Rieger A; Trauner M; Peck-Radosavljevic M;
    Antivir Ther; 2012; 17(7):1327-34. PubMed ID: 22948263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
    Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
    N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.
    Di Marco V; Almasio PL; Ferraro D; Calvaruso V; Alaimo G; Peralta S; Di Stefano R; Craxì A
    J Hepatol; 2007 Oct; 47(4):484-91. PubMed ID: 17692985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis.
    Rincon D; Ripoll C; Lo Iacono O; Salcedo M; Catalina MV; Alvarez E; Nuñez O; Matilla AM; Clemente G; Bañares R
    Am J Gastroenterol; 2006 Oct; 101(10):2269-74. PubMed ID: 17032192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; Marxuach-Cuétara AM; López-Torres A; Jiménez-Rivera J
    J Hepatol; 2007 Apr; 46(4):613-9. PubMed ID: 17316873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus guidelines for the management of hepatitis C infection.
    Consensus Guidelines Committee for the Management of Hepatitis C Infection
    Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
    Mukherjee S; Lyden E
    Hepatogastroenterology; 2006; 53(70):561-5. PubMed ID: 16995462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
    Everson GT; Hoefs JC; Seeff LB; Bonkovsky HL; Naishadham D; Shiffman ML; Kahn JA; Lok AS; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Morishima C;
    Hepatology; 2006 Dec; 44(6):1675-84. PubMed ID: 17133499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.
    Reiberger T; Ferlitsch A; Sieghart W; Kreil A; Breitenecker F; Rieger A; Schmied B; Gangl A; Peck-Radosavljevic M
    J Viral Hepat; 2010 Jun; 17(6):400-9. PubMed ID: 19780945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
    Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
    J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of interferon-based therapy for chronic hepatitis C.
    Yu ML; Huang CF; Dai CY; Huang JF; Chuang WL
    Oncology; 2007; 72 Suppl 1():16-23. PubMed ID: 18087178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Does antiviral therapy improve the clinical course of cirrhosis due to hepatitis C virus infection?].
    Diago M
    Gastroenterol Hepatol; 2007 Feb; 30(2):85-92. PubMed ID: 17335716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
    Manolakopoulos S; Triantos C; Theodoropoulos J; Vlachogiannakos J; Kougioumtzan A; Papatheodoridis G; Tzourmakliotis D; Karamanolis D; Burroughs AK; Archimandritis A; Raptis S; Avgerinos A
    J Hepatol; 2009 Sep; 51(3):468-74. PubMed ID: 19616339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
    Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
    Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.